Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexaria Bioscience (LEXX) Liabilities from Discontinued Operations (2020)

Lexaria Bioscience's Liabilities from Discontinued Operations history spans 1 years, with the latest figure at 250.0 for Q3 2020.

  • For Q3 2020, Liabilities from Discontinued Operations changed N/A year-over-year to 250.0; the TTM value through Aug 2020 reached 250.0, changed N/A, while the annual FY2020 figure was 250.0, N/A changed from the prior year.
  • Liabilities from Discontinued Operations for Q3 2020 was 250.0 at Lexaria Bioscience, roughly flat from 250.0 in the prior quarter.
  • Across five years, Liabilities from Discontinued Operations topped out at 250.0 in Q2 2020 and bottomed at 250.0 in Q2 2020.